GARDASIL^®9 is a vaccine indicated for individuals 9 through 45 years of age for the prevention of infection caused by the human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 and the following diseases associated with the HPV types included in the vaccine: certain head and neck cancers, such as throat and back of mouth cancers, caused by HPV types 16, 18, 31, 33, 45, 52, and 58. GARDASIL^®9 has been approved with conditions. This means it has passed Health Canada’s review and can be bought and sold in Canada, but the manufacturer has agreed to complete more studies to make sure the vaccine works the way it should. For more information, talk to your healthcare professional.

GARDASIL^®9 is also indicated for individuals 9 through 45 years of age for the prevention of infection caused by the human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 and the following diseases associated with the HPV types included in the vaccine: cervical, vulvar, vaginal and anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58; genital warts (condyloma acuminata) caused by HPV types 6 and 11; abnormal and precancerous cervical lesions (changes in cells of the cervix that have a risk of turning into cancer) as found in a Pap test caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58; abnormal and precancerous vaginal, vulvar (outside of the female genital area) and anal lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.

GARDASIL^®9 does not protect the person getting the vaccine from a disease that is caused by other types of HPV, other viruses, or bacteria, and from HPV types that he/she may already have; but most people do not have all types contained in the vaccine. GARDASIL^®9 does not treat HPV infection, cancers and diseases, or prevent its complications. GARDASIL^®9 may not fully protect each person who gets it. GARDASIL^®9 does not remove the need for screening for cervical, vulvar, vaginal, anal, and certain head and neck cancers, such as throat and back of mouth cancers; women should still get routine cervical cancer screening. GARDASIL^®9 is not recommended for use in pregnant women and should only be used during pregnancy if a doctor or healthcare professional decides it is clearly needed. Women who become pregnant before completion of the vaccine series should complete their vaccination schedule after childbirth. If you are breastfeeding, talk to your doctor or healthcare professional. GARDASIL^®9 may cause some side effects and allergic reactions. The most common side effects seen are pain, swelling, redness, itching, bruising, bleeding, a lump where the shot is given, headache, fever, nausea, dizziness, tiredness, diarrhea, abdominal pain and sore throat. Fainting can happen after getting an HPV vaccine. Signs of an allergic reaction may include difficulty breathing, wheezing (bronchospasm), hives and rash. This is not a complete list of side effects; for any unexpected effects while taking GARDASIL^®9, contact your doctor or pharmacist. Contact your doctor or healthcare professional to determine if GARDASIL^®9 is an appropriate option for you.

Information about GARDASIL^®9 is provided in the Product Monograph and Consumer Information, available here.

HPV=human papillomavirus.